The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial.
- DOI
- 10.1016/j.jtha.2025.11.024
- Published
- 2026 Mar
- Container
- Journal of thrombosis and haemostasis : JTH
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtha.2025.11.024,
title = {The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial.},
author = {van Es N and Scheres LJJ and Sanfilippo KM and Büller H and Carrier M and Di Nisio M and Grosso M and Lopes RD and McIntyre WF and Redfors B and Segers A and Verhamme P and Weitz JI and Bossuyt PM and Siegal DM},
year = {2026},
journal = {Journal of thrombosis and haemostasis : JTH},
doi = {10.1016/j.jtha.2025.11.024},
url = {https://doi.org/10.1016/j.jtha.2025.11.024}
}RIS
TY - JOUR TI - The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. AU - van Es N AU - Scheres LJJ AU - Sanfilippo KM AU - Büller H AU - Carrier M AU - Di Nisio M AU - Grosso M AU - Lopes RD AU - McIntyre WF AU - Redfors B AU - Segers A AU - Verhamme P AU - Weitz JI AU - Bossuyt PM AU - Siegal DM PY - 2026 JO - Journal of thrombosis and haemostasis : JTH DO - 10.1016/j.jtha.2025.11.024 UR - https://doi.org/10.1016/j.jtha.2025.11.024 ER -
APA
N, V. E., LJJ, S., KM, S., H, B., M, C., M, D. N., M, G., RD, L., WF, M., B, R., A, S., P, V., JI, W., PM, B., & DM, S. (2026). The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial.. Journal of thrombosis and haemostasis : JTH. https://doi.org/10.1016/j.jtha.2025.11.024
Source records
- pubmed · retrieved 2026-09-25T23:20:42.359Z